CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
Feb. 28, 2015	Feb. 28, 2014
Cash flows from operating activities:
Net (loss)	$ (574,483)us-gaap_NetIncomeLoss	$ (384,532)us-gaap_NetIncomeLoss
Adjustments to reconcile net (loss) to net cash (used in)operating activities:
Depreciation and amortization	192,670us-gaap_DepreciationAndAmortization	148,624us-gaap_DepreciationAndAmortization
Stock option expense	6,063us-gaap_StockOptionPlanExpense	11,003us-gaap_StockOptionPlanExpense
Change in provision for losses on accounts receivable	(12,993)us-gaap_ProvisionForDoubtfulAccounts	4,675us-gaap_ProvisionForDoubtfulAccounts
Gain on disposal of fixed asset	(665)
Inventory reserve	7,328	(6,713)
Decrease in deferred rent liability	(14,834)	(10,109)
Changes in assets and liabilities:
Accounts receivable	529,304	(304,783)
Inventories	(352,354)us-gaap_IncreaseDecreaseInInventories	(360,407)us-gaap_IncreaseDecreaseInInventories
Prepaid expenses and other assets	(26,521)	55,671
Accounts payable and other accrued expenses	(73,902)	81,323
Other assets	(14,788)
Accrued compensation	16,262	(87,654)
Net cash (used in) operating activities	(318,913)	(852,902)
Cash flows from investing activities:
Proceeds from sale of equipment	1,900
Increases in intangibles	(14,135)
Purchases of property and equipment	(8,656)	(117,365)
Net cash used in investing activities	(20,891)	(117,365)
Cash flows from financing activities:
Proceeds from sale of common stock		150,000
Proceeds from exercise of stock options	4,355	17,275
Net cash provided by financing activities	4,355	167,275
Effect of exchange rate changes in cash	(1,987)	(1,114)
Net decrease in cash and cash equivalents	(337,436)	(804,106)
Cash and cash equivalents at beginning of period	1,509,125	2,469,796
Cash and cash equivalents at end of period	1,171,689	1,665,690
Cash paid during the period for:
Interest	17us-gaap_InterestPaid	80us-gaap_InterestPaid
Income taxes	800us-gaap_IncomeTaxesPaid	9,535us-gaap_IncomeTaxesPaid
Non-Cash investment disclosure:
Payment of international regulatory approval fees in Exchange for $100,000 due on agreement to purchase Biomerica restricted stock		$ 100,000

Name:	bmra_CashPaidDuringThePeriodForAbstract
Namespace Prefix:	bmra_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The increase (decrease) during the period in the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.